Skip to main content
CRON logo

CRON · Cronos Group Inc.

Track CRON — free
$3.19 -0.08 (-2.45%) At close · Nov 17
Market Cap
$1.17B
Shares
366.47M
Volume · Nov 17 837.03K Avg daily vol (3M) 1.06M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.19 Open$3.26 Day$3.19–3.28 52W close$2.30–3.72 Avg vol 30d1.0M Short int4.2M · 1.1% of shares · 4.9d Short vol37% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Earnings call
Record third-quarter net revenue rises 75% to $63.5 million

Kronos reported record third-quarter 2026 net revenue of $63.5 million, up 75% year-over-year, with record adjusted EBITDA of $17.1 million.

2 source passages
In the third quarter of 2026, Crotus reported consolidated net revenue of $63.5 million, a 75% increase year-over-year. Adjusted EBITDA in the third quarter was a record $17.1 million, an improvement of $11.4 million year-over-year, driven by higher gross profit, partially offset by high operating expenses. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue and profitability rise sharply

Cronos reported third-quarter net revenue of $63.5 million, up $27.1 million, and gross profit of $32.3 million, up $14.0 million. Nine-month net revenue was $161.7 million and gross profit $79.9 million.

Revenue $63.45M ▲ 74.6% Net income $13.8M ▼ 46.8% Diluted EPS $0.04 ▼ 42.9%
Read from the MD&A section
2 source passages
For the three months ended September 30, 2026, we reported consolidated net revenue of $63.5 million, representing an increase of $27.1 million from the three months ended September 30, 2025. For the nine months ended September 30, 2026, we reported consolidated net revenue of $161.7 million, representing an increase of $59.6 million from the nine months ended September 30, 2025. For the three months ended September 30, 2026, we reported gross profit of $32.3 million, representing an increase of $14.0 million from the three months ended September 30, 2025. For the nine months ended September 30, 2026, we reported gross profit of $79.9 million, representing an increase of $33.3 million from the nine months ended September 30, 2025. Open the document at this passage
Nov 5
Current report 8-K
Organic revenue rose 73%, Adjusted EBITDA reached $17.1 million

Cronos Group Inc. reported Q3 2026 net revenue of $63.5 million, up 75% year-over-year and 73% organically on a constant-currency basis, with Adjusted EBITDA of $17.1 million.

Financial results Read from the first part of this long document
5 source passages
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2026 third quarter business results. Net revenue in Q3 2026 increased by 73% year-over-year on an organic, constant-currency basis Net revenue of $63.5 million in Q3 2026 increased by $27.1 million from Q3 2025. Adjusted EBITDA of $17.1 million in Q3 2026 improved by $11.4 million from Q3 2025. Net revenue | 63,450 | | 36,339 | | 27,111 | 75 | % Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$206.20M
Trailing 12 months
Net income (TTM)
$54.99M
Trailing 12 months
Revenue growth YoY
+74.6%
Year over year
Operating margin
3.4%
Trailing 12 months
P / E (TTM)
19.9
Trailing earnings · reciprocal yield 5.0%
FCF yield
5.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$741.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.7%
Year over year · fewer shares
Price change (1Y)
+31.8%
Trailing year
Short interest
1.1%
Latest settlement · 4.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Q3 net revenue rose to $63.5 million and Adjusted EBITDA reached a record $17.1 million, with gross profit up $14.0 million. Net income fell to $17.8 million as operating expenses rose to $23.3 million, and price compression and lumpy international sales remain risks.

Bullish
  • + Q3 net revenue of $63.5 million, up $27.1 million year-over-year, driven by flower sales in Israel and other countries. new
  • + Adjusted EBITDA of $17.1 million, a record, improved by $11.4 million year-over-year on higher gross profit. new
  • + Gross profit of $32.3 million, up $14.0 million year-over-year, driven by higher average sales prices and volumes. new
  • + International business ex-Israel delivered record net revenue, increasing 614% year-over-year, led by Germany. new
  • + Cronos Israel delivered its eleventh consecutive quarter of record net revenue, up 33% year-over-year (19% on a constant-currency basis). new
  • + Completed the acquisition of CanAdelaar B.V. on October 15, 2026, establishing a leadership position in Europe's largest adult-use cannabis market. new
Bearish
  • − Net income of $17.8 million, down from $28.3 million a year earlier, on lower other income, higher operating expenses and a tax provision. new
  • − Total operating expenses of $23.3 million, up $4.4 million year-over-year, driven by G&A and sales and marketing. new
  • − Seasonal softness in Canadian Provincial Board purchasing is expected in Q4 versus Q3, and international sales can be lumpy. new
  • − Gross margins may vary due to potential price compression, mix and production volumes. new
  • − Management expects price compression in the Netherlands market now that suppliers have ramped up. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg −4%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 63%
mid-range
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +12%
trailing
YTD return +21%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.13% of shares out · ▲ +4.9% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
194 holders — mid 3-yr range
Squeeze score 56
elevated · 0–100
Fundamentals
Excellent
Revenue growth +25%
Y/Y
Gross margin 43%
expanding
EPS growth −118%
Y/Y
Free cash flow $149.0K
Valuation P/E 19.9
in line
Buyback $42.1M
remaining
Balance sheet $791.8M
net cash
Quant / Vol
risk profile
Moderate
Volatility 41%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 9, 2022
Expenses in connection with the Realignment · as a result of the Realignment $6.4M
Capital expenditures as a result of the Realignment · as a result of the Realignment $2.2M
Previous outlook earlier release · from the 8-K filed Mar 1, 2022

Still-open targets the latest release did not restate under the same label.

Capital expenditures · $2.5M
Guided vs delivered · last 1 settled
Net revenue full-year 2023
guided $100M – $110M
$87.24M Miss −16.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
63% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.13% of shares out · ▲ +4.9% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
194 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 63% Range high $4
vs 200-day avg +10% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Gross Margin non-GAAP 48% Six months ended June 30, 2026 —
Cronos Israel net revenue growth year-over-year 60% Q2 2026 —
Shares repurchased 12.3M First half of 2026 —
Spinach disposable vape market share 8.2% Q2 2026 —
Spinach edibles market share 20.8% Q2 2026 —
Spinach flower market share 5.4% Q2 2026 —
Spinach infused pre-rolls market share 3.5% Q2 2026 —
Spinach national market share 5.9% Q2 2026 —
Spinach pre-rolls market share 3.1% Q2 2026 —
Spinach total vape market share 10.6% Q2 2026 —
Spinach vape cartridge market share 11.8% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRON
Cronos Group Inc.
this stock
$1.17B +21.3% +24.6% 19.9 1.1%
TAK
Takeda Pharmaceutical Co Ltd
$69.14B +38.8% — — 0.1%
GALDY
Galderma Group AG
$52.00B +7.6% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.73B +36.6% +4.3% 96.9 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
194
% held
13.2%
Net QoQ
+755.2K sh
Top holder
D. E. Shaw & Co., Inc.
Held Float
View
Held by Funds
Fund positions
44
View
Short & Settlement
Short Interest Rising
Shares short
4.2M
Days to cover
4.9d
Change
+192.8K sh
View
Short Volume
Short vol %
37%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$16
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
47.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
John A. Yarmuth
Amount
$1.0K–$15.0K
Traded
Feb 12, 2021
View
Financials
Financials
Revenue (FY)
$146.6M
Net income (FY)
$-9.4M
EPS diluted
$-0.02
View
Buybacks
Authorized
$50.0M
Remaining
$42.1M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
16

Cronos reported third-quarter net revenue of $63.5 million, up $27.1 million, and gross profit of $32.3 million, up $14.0 million. Nine-month net revenue was $161.7 million and gross profit $79.9 million.

View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Cronos Completes Acquisition of C…
Published
Oct 15, 2026
View

Performance

5D 20D 120D MTD YTD
CRON -6.5% -2.7% +12.3% -3.3% +21.3%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -4.1% +2.0% +15.3% -0.3% +13.9%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$50.00M
Spent (derived)
$7.90M
Remaining
$42.10M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1656472 CUSIP 22717L101 13F (30d) 213 filings 181 filers Visit website Investor relations